European Neuropsychopharmacology
Volume 21, Issue 4 , Pages 344-353 , April 2011

Mapping of CBV changes in 5-HT1A terminal fields by functional MRI in the mouse brain

  • Thomas Mueggler

      Affiliations

    • Institute for Biomedical Engineering, University and ETH Zurich, Zurich, Switzerland
    • Current address: F. Hoffmann-La Roche Ltd., Pharmaceutical Research Neuroscience, CH-4070 Basel, Switzerland. Tel.: +41 61 687 4027; fax: +41 61 687 1910.
    • Contributed equally to this work.
    • ,
  • Florence Razoux

      Affiliations

    • Institute for Biomedical Engineering, University and ETH Zurich, Zurich, Switzerland
    • Contributed equally to this work.
    • ,
  • Holger Russig

      Affiliations

    • Brain Research Institute, University and ETH Zurich, Zurich, Switzerland
    • ,
  • Anna Buehler

      Affiliations

    • Institute for Biomedical Engineering, University and ETH Zurich, Zurich, Switzerland
    • ,
  • Tamara B. Franklin

      Affiliations

    • Brain Research Institute, University and ETH Zurich, Zurich, Switzerland
    • ,
  • Christof Baltes

      Affiliations

    • Institute for Biomedical Engineering, University and ETH Zurich, Zurich, Switzerland
    • ,
  • Isabelle M. Mansuy

      Affiliations

    • Brain Research Institute, University and ETH Zurich, Zurich, Switzerland
    • ,
  • Markus Rudin

      Affiliations

    • Institute for Biomedical Engineering, University and ETH Zurich, Zurich, Switzerland
    • Institute of Pharmacology and Toxicology, University Zurich, Zurich, Switzerland
    • Corresponding Author InformationCorresponding author. Institute for Biomedical Engineering, University and ETH Zurich, Institute of Pharmacology and Toxicology, University of Zurich, HIT E.22.4, Wolfgang Pauli Strasse 27, CH-8093 Zurich, Switzerland. Tel.: +41 44 633 7604; fax: +41 44 633 1187.

Received 11 December 2009 ,Revised 14 June 2010 ,Accepted 19 June 2010.

References 

  1. Albert PR, Lemonde S. 5-HT1A receptors, gene repression, and depression: guilt by association. Neuroscientist. 2004;10:575–593
  2. Anderson IM, McKie S, Elliott R, Williams SR, Deakin JF. Assessing human 5-HT function in vivo with pharmacoMRI. Neuropharmacology. 2008;55:1029–1037
  3. Arvidsson LE, Hacksell U, Nilsson JL, Hjorth S, Carlsson A, Lindberg P, et al. 8-Hydroxy-2-(di-n-prpylamino)tetralin, a new centrally acting 5-hydroxytryptamine receptor agonist. J. Med. Chem. 1981;24:921–923
  4. Assié MB, Koek W. Effects of 5-HT1A receptor antagonists on hippocampal 5-hydroxytryptamine levels: (S)-WAY100135, but not WAY-100635, has partial agonist properties. Eur. J. Pharmacol. 1996;304:15–21
  5. Baltes C, Radzwill N, Bosshard S, Marek D, Rudin M. Micro MR imaging of the mouse brain using a novel 400MHz cryogenic quadrature RF probe. NMR Biomed. 2009;22:834–842
  6. Bard JA, Zgombick J, Adham N, Vaysse P, Branchek TA, Weinshank RL. Cloning of a novel human serotonin receptor (5-HT7) positively linked to adenylate cyclase. J. Biol. Chem. 1993;268:23422–23426
  7. Barnes NM, Sharp T. A review of central 5-HT receptors and their function. Neuropharmacology. 1999;38:1083–1152
  8. Blier P, Ward NM. Is there a role for 5-HT1A agonists in the treatment of depression?. Biol. Psychiatry. 2003;53:193–203
  9. Blier P, Piñeyro G, el Mansari M, Bergeron R, de Montigny C. Role of somatodendritic 5-HT autoreceptors in modulating 5-HT neurotransmission. Ann. NY Acad. Sci. 1998;861:204–216
  10. Bockaert J, Claeysen S, Bécamel C, Dumuis A, Marin P. Neuronal 5-HT metabotropic receptors: fine-tuning of their structure, signaling, and roles in synaptic modulation. Cell Tissue Res. 2006;326:553–572
  11. Borsook D, Becerra L, Hargreaves R. A role for fMRI in optimizing CNS drug development. Nat. Rev. Drug Discov. 2006;5:411–424
  12. Celada P, Puig MV, Martín-Ruiz R, Casanovas JM, Artigas F. Control of the serotonergic system by the medial prefrontal cortex: potential role in the etiology of PTSD and depressive disorders. Neurotox. Res. 2002;4:409–419
  13. Centurion D, Mehotra S, Sánchez-López A, Gupta S, Maassen VanDenBrink A, Villalón CM. Potential vascular α1-adrenoceptor blocking properties of an array of 5-HT receptor ligands in the rat. Eur. J. Pharmacol. 2006;535:234–242
  14. Chen YC, Galpern WR, Brownell AL, Matthews RT, Bogdanov M, Isacson O, et al. Detection of dopaminergic neurotransmitter activity using pharmacologic MRI: correlation with PET, microdialysis, and behavioral data. Magn. Reson. Med. 1997;38:389–398
  15. Chessell IP, Francis PT, Pangalos MN, Pearson RC, Bowen DM. Localisation of muscarinic (m1) and other neurotransmitter receptors on corticofugalprojecting pyramidal neurones. Brain Res. 1993;632:86–94
  16. Czyrak A, Czepiel K, Mackowiak M, Chocyk A, Wedzony K. Serotonin 5-HT1A receptors might control the output of cortical glutamatergic neurons in rat cingulate cortex. Brain Res. 2003;989:42–51
  17. Descarries L, Watkins KC, Garcia S, Beaudet A. The serotonin neurons in nucleus raphe dorsalis of adult rat: a light and electron microscope radioautographic study. J. Comp. Neurol. 1982;207:239–254
  18. Drevets WC, Frank E, Price JC, Kupfer DJ, Holt D, Greer PJ, et al. PET imaging of serotonin 1A receptor binding in depression. Biol. Psychiatry. 1999;46:1375–1387
  19. Fletcher A, Bill DJ, Bill SJ, Cliffe IA, Dover GM, Forster EA, et al. WAY100135: a novel, selective antagonist at presynaptic and postsynaptic 5-HT1A receptors. Eur. J. Pharmacol. 1993;237:283–291
  20. Fletcher A, Forster EA, Bill DJ, Brown G, Cliffe IA, Hartley JE, et al. Electrophysiological, biochemical, neurohormonal and behavioural studies with WAY-100635, a potent, selective and silent 5-HT1A receptor antagonist. Behav. Brain Res. 1996;73:337–353
  21. Freo U. Cerebral metabolic effects of serotonin drugs and neurotoxins. Life Sci. 1996;59:877–891
  22. Garner M, Möhler H, Stein DJ, Mueggler T, Baldwin DS. Research in anxiety disorders: from the bench to the bedside. Eur. Neuropsychopharmacol. 2009;19:381–390
  23. Gingrich JA, Hen R. Dissecting the role of the serotonin system in neuropsychiatric disorders using knockout mice. Psychopharmacology. 2001;155:1–10
  24. Graeff FG. On serotonin and experimental anxiety. Psychopharmacology. 2002;163:467–476
  25. Gross C, Zhuang XX, Stark K, Ramboz S, Oosting R, Kirby L, et al. Serotonin(1A)receptor acts during development to establish normal anxiety-like behaviour in the adult. Nature. 2002;416:396–400
  26. Gustafson EL, Durkin MM, Bard JA, Zgombick J, Branchek TA. A receptor autoradiographic and in situ hybridization analysis of the distribution of the 5-HT7 receptor in rat brain. Br. J. Pharmacol. 1996;117:657–666
  27. Hackler EA, Turner GH, Gresch PJ, Sengupta S, Deutch AY, Avison MJ, et al. 5-Hydroxytryp.tamine2C receptor contribution to m-chlorophenylpiperazine and N-methyl-beta-carboline-3-carboxamide-induced anxiety-like behavior and limbic brain activation. J. Pharmacol. Exp. Ther. 2007;320:1023–1029
  28. Hannon J, Hoyer D. Molecular biology of 5-HT receptors. Behav. Brain Res. 2008;195:198–213
  29. Hedlund PB, Kelly L, Mazurb C, Lovenberg T, Sutcliffe JG, Bonaventure P. 8-OH-DPAT acts on both 5-HT1A and 5-HT7 receptors to induce hypothermia in rodents. Eur. J. Pharmacol. 2004;487:125–132
  30. Hennig J, Nauerth A, Friedburg H. RARE imaging: a fast imaging method for clinical MR. Magn. Reson. Med. 1986;3:823–833
  31. Hillegaart V, Hjorth S, Ahlenius S. Effects of 5-HT and 8-OH-DPAT on forebrain monoamine synthesis after local application into the median and dorsal raphe nuclei of the rat. J. Neural Transm. Gen. Sect. 1990;81:131–145
  32. Hirvonen J, Karlsson H, Kajander J, Lepola A, Markkula J, Rasi-Hakala H, et al. Decreased brain serotonin 5-HT1A receptor availability in medication-naive patients with major depressive disorder: an in-vivo imaging study using PET and (carbonyl-11C)WAY-100635. Int. J. Neuropsychopharmacol. 2008;11:465–476
  33. Hjorth S, Sharp T. Effect of the 5-HT1A receptor agonist 8-OH-DPAT on the release of 5-HT in dorsal and median raphe-innervated rat brain regions as measured by in vivo microdialysis. Life Sci. 1991;48:1779–1786
  34. Houston GC, Papadakis NG, Carpenter TA, Hall LD, Mukherjee B, James MF, et al. Mapping of brain activation in response to pharmacological agents using fMRI in the rat. Magn. Reson. Imaging. 2001;19:905–919
  35. Hoyer D, Pazos A, Probst A, Palacios JM. Serotonin receptors in the human brain. I. Characterization and autoradiographic localization of 5-HT1A recognition sites. Apparent absence of 5-HT1B recognition sites. Brain Res. 1986;376:85–96
  36. Jagoda EM, Lang L, Tokugawa J, Simmons A, Ma Y, Contoreggi C, et al. Development of 5-HT1A receptor radioligands to determine receptor density and changes in endogenous 5-HT. Synapse. 2006;59:330–341
  37. Jones N, O'Neill MJ, Tricklebank M, Libri V, Williams SC. Examining the neural targets of the AMPA receptor potentiator LY404187 in the rat brain using pharmacological magnetic resonance imaging. Psychopharmacology. 2005;180:743–751
  38. Kumar JS, Mann JJ. PET tracers for 5-HT(1A) receptors and uses thereof. Drug Discov. Today. 2007;12:748–756
  39. Kuriwaki J, Nishijo H, Kondoh T, Uwano T, Torii K, Katsuki M, et al. Comparison of brain activity between dopamine D2 receptor-knockout and wild mice in response to dopamine agonist and antagonist assessed by fMRI. Neurosignals. 2004;13:227
  40. Lanfumey L, Hamon M. Central 5-HT(1A) receptors: regional distribution and functional characteristics. Nucl. Med. Biol. 2000;27:429–435
  41. Lanzenberger RR, Mitterhauser M, Spindelegger C, Wadsak W, Klein N, Mien LK, et al. Reduced serotonin-1A receptor binding in social anxiety disorder. Biol. Psychiatry. 2007;61:1081–1089
  42. Laporte AM, Lima L, Gozlan H, Hamon M. Selective in vivo labelling of brain 5-HT1A receptors by (3H)WAY 100635 in the mouse. Eur. J. Pharmacol. 1994;271:505–514
  43. Martin C, Sibson NR. Pharmacological MRI in animal models: a useful tool for 5-HT research?. Neuropharmacology. 2008;55:1038–1047
  44. Martín-Ruiz R, Ugedo L. Electrophysiological evidence for postsynaptic 5-HT(1A) receptor control of dorsal raphe 5-HT neurones. Neuropharmacology. 2001;41:72–78
  45. Mueggler T. Magnetic resonance imaging and spectroscopy in transgenic mice modeling Alzheimer's disease. In:  Beckmann N editors. In-vivo MRI/MRS in Biological Systems. New York: Taylor & Francis Group; 2006;p. 95–110
  46. Mueggler T, Baumann D, Rausch M, Rudin M. Bicuculline-induced brain activation in mice detected by functional magnetic resonance imaging. Magn. Reson. Med. 2001;46:292–298
  47. Mueggler T, Sturchler-Pierrat C, Baumann D, Rausch M, Staufenbiel M, Rudin M. Compromised hemodynamic response in amyloid precursor protein transgenic mice. J. Neurosci. 2002;22:7218–7224
  48. Mueggler T, Baumann D, Rausch M, Staufenbiel M, Rudin M. Age-dependent impairment of somatosensory response in the amyloid precursor protein 23 transgenic mouse model of Alzheimer's disease. J. Neurosci. 2003;23:8231–8236
  49. Neumeister A, Young T, Stastny J. Implications of genetic research on the role of the serotonin in depression: emphasis on the serotonin type 1A receptor and the serotonin transporter. Psychopharmacology. 2004;174:512–524
  50. Olivier B, Pattij T, Wood SJ, Oosting R, Sarnyai Z, Toth M. The 5-HT(1A) receptor knockout mouse and anxiety. Behav. Pharmacol. 2001;12:439–450
  51. Parks CL, Robinson PS, Sibille E, Shenk T, Toth M. Increased anxiety of mice lacking the serotonin(1A) receptor. Proc. Natl. Acad. Sci. U. S. A. 1998;95:10734–10739
  52. Pattij T, Groenink L, Oosting RS, van der Gugten J, Maes RA, Olivier B. GABA(A)-benzodiazepine receptor complex sensitivity in 5-HT(1A) receptor knockout mice on a 129/Sv background. Eur. J. Pharmacol. 2002;447:67–74
  53. Paxinos G, Franklin KBJ. The Mouse Brain in Stereotaxic Coordinates. San Diego: Academic Press; 2001;
  54. Ramboz S, Oosting R, Amara DA, Kung HF, Blier P, Mendelsohn M, et al. Serotonin receptor 1A knockout: an animal model of anxiety-related disorder. Proc. Natl. Acad. Sci. U. S. A. 1998;95:14476–14481
  55. Ratering D, Baltes C, Nordmeyer-Massner J, Marek D, Rudin M. Performance of a 200-MHz cryogenic RF probe designed for MRI and MRS of the murine brain. Magn. Reson. Med. 2008;59:1440–1447
  56. Reese T, Bjelke B, Porszasz R, Baumann D, Bochelen D, Sauter A, et al. Regional brain activation by bicuculline visualized by functional magnetic resonance imaging. Time-resolved assessment of bicuculline-induced changes in local cerebral blood volume using an intravascular contrast agent. NMR Biomed. 2000;13:43–49
  57. Rudin M, Mueggler T, Allegrini PR, Baumann D, Rausch M. Characterization of CNS disorders and evaluation of therapy using structural and functional MRI. Anal. Bioanal. Chem. 2003;377:973–981
  58. Savitz J, Lucki I, Drevets WC. 5-HT(1A) receptor function in major depressive disorder. Prog. Neurobiol. 2009;88:17–31
  59. Scanley BE, Kennan RP, Gore JC. Changes in rat cerebral blood volume due to modulation of the 5-HT(1A) receptor measured with susceptibility enhanced contrast MRI. Brain Res. 2001;913:149–155
  60. Sprouse JS, Aghajanian GK. Responses of hippocampal pyramidal cells to putative serotonin 5-HT1A and 5-HT1B agonists: a comparative study with dorsal raphe neurons. Neuropharmacology. 1988;27:707–715
  61. Stark JA, Davies KE, Williams SR, Luckman SM. Functional magnetic resonance imaging and c-Fos mapping in rats following an anorectic dose of m-chlorophenylpiperazine. Neuroimage. 2006;31:1228–1237
  62. Stark JA, McKie S, Davies KE, Williams SR, Luckman SM. 5-HT2C antagonism blocks blood oxygen level-dependent pharmacological-challenge magnetic resonance imaging signal in rat brain areas related to feeding. Eur. J. Neurosci. 2008;27:457–465
  63. Sullivan GM, Oquendo MA, Simpson N, Van Heertum RL, Mann JJ, Parsey RV. Brain serotonin 1A receptor binding in major depression is related to psychic and somatic anxiety. Biol. Psychiatry. 2005;58:947–954
  64. Toth M. 5-HT1A receptor knockout mouse as a genetic model of anxiety. Eur. J. Pharmacol. 2003;463:177–184
  65. Van der Linden A, Van Camp N, Ramos-Cabrer P, Hoehn M. Current status of functional MRI on small animals: application to physiology, pathophysiology, and cognition. NMR Biomed. 2007;20:522–545
  66. Wood MD. Therapeutic potential of 5-HT2C receptor antagonists in the treatment of anxiety disorders. Curr. Drug Targets CNS Neurol. Disord. 2003;2:383–387
  67. Yoshio R, Taniguchi T, Itoh H, Muramatsu I. Affinity of serotonin receptor antagonists and agonists to recombinant and native alpha1-adrenoceptor subtypes. Jpn J. Pharmacol. 2001;86:189–195

PII: S0924-977X(10)00137-9

doi: 10.1016/j.euroneuro.2010.06.010

European Neuropsychopharmacology
Volume 21, Issue 4 , Pages 344-353 , April 2011

Article Tools

* Image Usage & Resolution